<DOC>
	<DOCNO>NCT00261417</DOCNO>
	<brief_summary>This 12-week study determine effect glucose lipid , safety , tolerability four dos tesaglitazar ( 0.25 , 0.5 , 0.75 1 mg ) compare placebo patient type 2 diabetes . Improvement dyslipidemia evaluate . The study comprise 2-week screening period , 4-week placebo run-in , 12-week randomized , double blind , parallel group , multi-center , placebo-controlled treatment period , 3-week follow-up .</brief_summary>
	<brief_title>Dose Response Study Japanese Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Provision write informed consent Men woman &gt; =18 year age Female patient : postmenopausal , hysterectomized Diagnosed type 2 diabetes Treated diet alone treatment single oral antidiabetic agent low dos two oral antidiabetic agent Type 1 diabetes New York Heart Association heart failure Class III IV Treatment chronic insulin History hypersensitivity intolerance peroxisome proliferatoractivated receptor agonist ( like Actos Avandia ) , fenofibrate , metformin 3hydroxy3methylglutaryl coenzyme A reductase inhibitor ( statin ) History druginduced myopathy druginduced creatine kinase elevation , liver enzyme elevation , neutropenia ( low white blood cell ) Creatinine level twice normal range Creatine kinase 3 time upper limit normal Received investigational product clinical study within 12 week Any clinically significant abnormality identify physical examination , laboratory test electrocardiogram , judgment investigator would compromise patient 's safety successful participation clinical study</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>